January 24, 2018 12:19 am | Updated 12:19 am IST - HYDERABAD
SMS Pharmaceuticals has received an establishment inspection report (EIR) for its Bachupally facility from the U.S. Food and Drug Administration (USFDA). “The facility was inspected by the USFDA in November 2017 and there were no Form 483 observations during the inspection,” the company said in a regulatory filing on Monday.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
